Steven S. Fu, MD, MSCE

Articles by Steven S. Fu, MD, MSCE

Initial Results of a Lung Cancer Screening Demonstration Project: A Local Program Evaluation

ByAngela E. Fabbrini, MPH,Sarah E. Lillie, PhD, MPH,Melissa R. Partin, PhD,Steven S. Fu, MD, MSCE,Barbara A. Clothier, MS, MA,Ann K. Bangerter, BS,David B. Nelson, PhD,Elizabeth A. Doro, BS,Brian J. Bell, MD,Kathryn L. Rice, MD

June 14th 2018

Results, lessons, and challenges of a local lung cancer screening program within a national demonstration project.

Treatment Barriers Among Younger and Older Socioeconomically Disadvantaged Smokers

ByPatrick J. Hammett, MA,Steven S. Fu, MD, MSCE,Diana J. Burgess, PhD,David Nelson, PhD,Barbara Clothier, MS, MA,Jessie E. Saul, PhD,John A. Nyman, PhD,Rachel Widome, PhD, MHS,Anne M. Joseph, MD, MPH

September 29th 2017

A conceptual framework was used to examine the influence of healthcare provider and psychosocial barriers on treatment utilization among younger and older socioeconomically disadvantaged smokers.

Latest Updated Articles

Treatment Barriers Among Younger and Older Socioeconomically Disadvantaged Smokers
September 29th 2017
Initial Results of a Lung Cancer Screening Demonstration Project: A Local Program Evaluation
June 14th 2018

Steven S. Fu, MD, MSCE

Articles by Steven S. Fu, MD, MSCE

Initial Results of a Lung Cancer Screening Demonstration Project: A Local Program Evaluation

Treatment Barriers Among Younger and Older Socioeconomically Disadvantaged Smokers

Latest Updated Articles

Trending on AJMC

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD